课题基金 / 基金详情

Preclinical Efficacy and Intermediate Endpoints Assays

Preclinical Efficacy and Intermediate Endpoints Assays
临床前疗效和中间终点检测
批准号：
7947672
负责人：
MICHAEL A. PEREIRA
金额：
$220.03万
依托单位：
OHIO STATE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2005
资助国家：
美国
项目状态：
已结题
起止时间：
2005-08-30 至 2011-08-29
来源：
https://reporter.nih.gov/project-details/7947672
关键词：
PreclinicalEfficacyIntermediateEndpointsAssays

项目摘要

项目成果

MICHAEL A. PEREIRA的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
NCI is using a stepwise approach to assess the potential of various agents to inhibit, reverse and/or delay the carcinogenic process in various organs. One of the preclinical evaluations of potential chemopreventive agents is the demonstration of agent efficacy in preventing cancer in laboratory animal models. Both carcinogen-induced and transgenic animals are used for this purpose. Another area of preclinical development in chemopreventive agents is the development of surrogate intermediate endpoint biomarkers. Such biomarkers must be translatable to the clinic trial situation in order to shorten the time required to evaluate agents clinically in Phase II trials.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Prevention of Lung Tumors by Agents using Concurrent and Sequential Treatment
  • 批准号：
    7658379
  • 项目类别：
  • 资助金额：
    $23.1万
  • 财政年份：
    2009
  • 负责人：
    MICHAEL A. PEREIRA
  • 依托单位：
    OHIO STATE UNIVERSITY
Chemoprevention of Tobacco Related Cancer in Animals
  • 批准号：
    6707998
  • 项目类别：
  • 资助金额：
    $55.93万
  • 财政年份：
    2002
  • 负责人：
    MICHAEL A. PEREIRA
  • 依托单位：
    OHIO STATE UNIVERSITY
Chemoprevention of Tobacco Related Cancer in Animals
Chemoprevention of Tobacco Related Cancer in Animals
海外基金